Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
Top Page
Acurx Pharmaceuticals
(NASDAQ:ACXP)
Rating:39Underperform
Price Target:―
Positive Factors
Clinical Efficacy
Ibezapolstat demonstrated a 94% clinical cure rate and no recurrence at 30 days, a key measure in CDI antibiotic development.
Partnership Prospects
Acurx should be able to find a partner for its development program, enhancing its prospects for growth and collaboration.
Regulatory Approval
Regulatory agencies in the U.S. and the E.U. have provided positive feedback to Acurx, supporting topics and plans related to manufacturing, non-clinical, and clinical aspects of the Phase 3 program and trial design.
Negative Factors
Funding Requirements
There needs to be a substantial capital raise and/or other funding resources to initiate a P3 program.
Market Valuation
A combination of macro- and micro- factors have contributed to significant pullbacks in valuations, including ACXP shares which are at an all-time low.
Acurx Pharmaceuticals (ACXP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.10M
Dividend YieldN/A
Average Volume (3M)56.20K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue GrowthN/A
EPS Growth53.79%
CountryUS
Employees4
SectorHealthcare
Sector Strength50
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.89
Shares Outstanding1,584,775
10 Day Avg. Volume76,562
30 Day Avg. Volume56,205
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$30.50Price Target Upside503.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Acurx Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAcurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
How the Company Makes MoneyAcurx Pharmaceuticals makes money primarily through the development and commercialization of its proprietary antibiotic compounds. As a clinical-stage company, its revenue model includes potential future sales of its lead product candidate, ibezapolstat, once it successfully completes clinical trials and receives regulatory approval. Additionally, Acurx may secure revenue through partnerships, licensing agreements, and collaborations with other pharmaceutical companies for the development and commercialization of its pipeline products. These partnerships could involve upfront payments, milestone payments, and royalties on sales. The company's earnings are also influenced by research grants and funding from governmental or non-governmental organizations interested in combating antibiotic-resistant infections.
Acurx Pharmaceuticals Earnings Call Summary
Earnings Call Date:Aug 12, 2025
(Q2-2025)
| % Change Since: 12.72%|
Next Earnings Date:Nov 18, 2025
Earnings Call Sentiment Positive
The earnings call highlighted several positive developments, including a new patent, additional funding, and significant clinical trial results. Financial results showed improvement with increased cash reserves and reduced expenses. However, challenges such as the reverse stock split and strategic delays in clinical trials were noted. Overall, the sentiment is cautiously optimistic.Q2-2025 Updates
Positive Updates
New Patent Granted
The Indian Patent Office granted a new patent for DNA polymerase IIIC inhibitors, significant for the ongoing preclinical antibiotic development program.
Equity Line of Credit
Closed an equity line of credit with Lincoln Park Capital for up to $12 million of additional funding.
Phase IIb Clinical Trial Publication
Published in Lancet Microbe, highlighted high clinical cure rates and no recurrence for ibezapolstat in C. difficile infection.
Financial Improvements
Cash increased to $6.1 million from $3.7 million, with a reduction in net loss and operating expenses compared to the previous year.
Cost Reduction
Research and development expenses decreased by $1.3 million, and general and administrative expenses decreased by $0.6 million compared to the previous year.
Negative Updates
Reverse Stock Split
Implemented a 1-for-20 reverse stock split to comply with NASDAQ listing requirements.
Challenges in Clinical Trials
Delay in fill/finish of ibezapolstat supply for Phase III trials due to strategic planning to maximize drug usage time.
Company Guidance
During the Acurx Pharmaceuticals second-quarter 2025 financial results conference call, several key metrics and updates were discussed. The company announced a significant decrease in research and development expenses, down to $0.5 million for the quarter compared to $1.8 million in the same period in 2024, and a reduction in general and administrative expenses to $1.7 million from $2.3 million. A net loss of $2.2 million or $1.89 per diluted share was reported for the quarter, showing an improvement from a net loss of $4.1 million or $5.21 per diluted share the previous year. The call highlighted strategic financial moves, including a $12 million equity line of credit and a warrant inducement agreement, which contributed to raising $3.4 million in gross proceeds. Additional updates included the publication of Phase IIb clinical trial data for ibezapolstat in Lancet Microbe, emphasizing the drug's high rates of clinical cure and potential impact on reducing the $5 billion annual U.S. cost burden for C. difficile infections. The company also implemented a 1-for-20 reverse stock split to comply with NASDAQ requirements, with cash reserves at $6.1 million by the end of the quarter.Acurx Pharmaceuticals Financial Statement Overview
Summary
Acurx Pharmaceuticals exhibits characteristics typical of early-stage biotech firms, such as no revenue and ongoing net losses. However, the absence of debt and ability to secure financing are positive aspects, though risks from cash outflows remain.Income Statement
Acurx Pharmaceuticals has consistently reported zero revenue over the years, indicating that it might still be in the development phase typical for many biotech companies. The company has incurred significant net losses, which is expected given the lack of revenue and high costs associated with R&D in this industry. However, the absence of revenue sources is a key concern.10
Very Negative
Balance Sheet
The company's balance sheet shows no debt, which indicates conservative financial management and lowers financial risk. However, the low equity ratio and consistent equity erosion due to net losses are concerning. The company has managed to maintain a positive equity position, though it has decreased over the years.35
Negative
Cash Flow
Acurx Pharmaceuticals is experiencing negative operating cash flows due to ongoing net losses, common for biotech firms without a marketable product yet. However, they have been able to secure financing to mitigate cash outflows, which is crucial for their operations. The lack of free cash flow growth is a significant downside.25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -10.00M | -14.10M | -14.58M | -12.09M | -12.75M | -4.60M |
| Net Income | -2.25B | -14.10B | -14.58M | -12.09M | -12.75M | -4.60M |
Balance Sheet | ||||||
| Total Assets | 6.16B | 3.86M | 7.71M | 9.38M | 13.25M | 3.22M |
| Cash, Cash Equivalents and Short-Term Investments | 6.06B | 3.71M | 7.47M | 9.11M | 12.96M | 3.17M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 66.50K |
| Total Liabilities | 2.59B | 3.24M | 3.04M | 2.06M | 843.91K | 522.43K |
| Stockholders Equity | 3.57B | 615.12K | 4.67M | 7.32M | 12.41M | 2.70M |
Cash Flow | ||||||
| Free Cash Flow | -3.73B | -10.38M | -9.80M | -7.54M | -5.01M | -3.35M |
| Operating Cash Flow | -3.73B | -10.38M | -9.80M | -7.54M | -5.01M | -3.35M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 7.87M | 6.62M | 8.16M | 3.69M | 14.80M | 4.04M |
Acurx Pharmaceuticals Technical Analysis
Negative
5.05
Price Trends
8.12
Negative
7.84
Negative
13.25
Negative
Market Momentum
-1.01
Negative
34.98
Neutral
69.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACXP, the sentiment is Negative. The current price of 5.05 is below the 20-day moving average (MA) of 5.99, below the 50-day MA of 8.12, and below the 200-day MA of 13.25, indicating a bearish trend. The MACD of -1.01 indicates Negative momentum. The RSI at 34.98 is Neutral, neither overbought nor oversold. The STOCH value of 69.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACXP.
Acurx Pharmaceuticals Risk Analysis
Acurx Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. Acurx Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acurx Pharmaceuticals Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $9.73M | ― | -81.33% | ― | -62.68% | 23.94% | |
51 Neutral | $7.73B | -0.08 | -44.77% | 2.23% | 22.72% | -1.44% | |
48 Neutral | $12.13M | ― | -137.09% | ― | 247.62% | -7.66% | |
42 Neutral | $12.02M | ― | -90.83% | ― | 650.00% | 85.42% | |
39 Underperform | $8.10M | ― | -285.93% | ― | ― | 53.79% | |
28 Underperform | $13.90M | ― | -169.59% | ― | ― | 34.39% | |
| ― | $16.38M | ― | -213.21% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
ACXP
Acurx Pharmaceuticals
5.05
-41.55
-89.16%
IBIO
Ibio
0.73
-1.33
-64.56%
WINT
Windtree Therapeutics
0.48
-526.52
-99.91%
BRTX
BioRestorative Therapies
1.50
-0.19
-11.24%
LIXT
Lixte Biotechnology Holdings
3.48
1.65
90.16%
BOLT
Bolt Biotherapeutics
4.78
-9.02
-65.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.